BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 20059643)

  • 1. Nanomedicine based approaches for the delivery of siRNA in cancer.
    Ozpolat B; Sood AK; Lopez-Berestein G
    J Intern Med; 2010 Jan; 267(1):44-53. PubMed ID: 20059643
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Liposomal siRNA nanocarriers for cancer therapy.
    Ozpolat B; Sood AK; Lopez-Berestein G
    Adv Drug Deliv Rev; 2014 Feb; 66():110-6. PubMed ID: 24384374
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lipid-based nanoparticles for siRNA delivery in cancer therapy: paradigms and challenges.
    Gomes-da-Silva LC; Fonseca NA; Moura V; Pedroso de Lima MC; Simões S; Moreira JN
    Acc Chem Res; 2012 Jul; 45(7):1163-71. PubMed ID: 22568781
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lipid-based nanotherapeutics for siRNA delivery.
    Schroeder A; Levins CG; Cortez C; Langer R; Anderson DG
    J Intern Med; 2010 Jan; 267(1):9-21. PubMed ID: 20059641
    [TBL] [Abstract][Full Text] [Related]  

  • 5. siRNA delivery to lung-metastasized tumor by systemic injection with cationic liposomes.
    Hattori Y; Nakamura A; Arai S; Kawano K; Maitani Y; Yonemochi E
    J Liposome Res; 2015; 25(4):279-86. PubMed ID: 25543847
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhancing endosomal escape for nanoparticle mediated siRNA delivery.
    Ma D
    Nanoscale; 2014 Jun; 6(12):6415-25. PubMed ID: 24837409
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Small interfering RNA delivery into the liver by cationic cholesterol derivative-based liposomes.
    Hattori Y; Machida Y; Honda M; Takeuchi N; Yoshiike Y; Ohno H; Onishi H
    J Liposome Res; 2017 Dec; 27(4):264-273. PubMed ID: 27345333
    [TBL] [Abstract][Full Text] [Related]  

  • 8. siRNA LNCs--a novel platform of lipid nanocapsules for systemic siRNA administration.
    David S; Resnier P; Guillot A; Pitard B; Benoit JP; Passirani C
    Eur J Pharm Biopharm; 2012 Jun; 81(2):448-52. PubMed ID: 22381204
    [TBL] [Abstract][Full Text] [Related]  

  • 9. siRNA applications in nanomedicine.
    Tokatlian T; Segura T
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2010; 2(3):305-15. PubMed ID: 20135697
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cation-free siRNA-cored nanocapsules for tumor-targeted RNAi therapy.
    Huang X; Li J; Li G; Ni B; Liang Z; Chen H; Xu C; Zhou J; Huang J; Deng S
    Acta Biomater; 2023 Apr; 161():226-237. PubMed ID: 36898473
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Single-step assembly of cationic lipid-polymer hybrid nanoparticles for systemic delivery of siRNA.
    Yang XZ; Dou S; Wang YC; Long HY; Xiong MH; Mao CQ; Yao YD; Wang J
    ACS Nano; 2012 Jun; 6(6):4955-65. PubMed ID: 22646867
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhanced siRNA delivery using cationic liposomes with new polyarginine-conjugated PEG-lipid.
    Kim HK; Davaa E; Myung CS; Park JS
    Int J Pharm; 2010 Jun; 392(1-2):141-7. PubMed ID: 20347025
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PEGylated DC-Chol/DOPE cationic liposomes containing KSP siRNA as a systemic siRNA delivery Carrier for ovarian cancer therapy.
    Lee J; Ahn HJ
    Biochem Biophys Res Commun; 2018 Sep; 503(3):1716-1722. PubMed ID: 30049442
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lipid-based nanoparticles in the systemic delivery of siRNA.
    Lin Q; Chen J; Zhang Z; Zheng G
    Nanomedicine (Lond); 2014 Jan; 9(1):105-20. PubMed ID: 24354813
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of cationic lipid in cationic liposomes on siRNA delivery into the lung by intravenous injection of cationic lipoplex.
    Hattori Y; Nakamura M; Takeuchi N; Tamaki K; Shimizu S; Yoshiike Y; Taguchi M; Ohno H; Ozaki KI; Onishi H
    J Drug Target; 2019 Feb; 27(2):217-227. PubMed ID: 30024300
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development and characterization of siRNA lipoplexes: Effect of different lipids, in vitro evaluation in cancerous cell lines and in vivo toxicity study.
    Khatri N; Baradia D; Vhora I; Rathi M; Misra A
    AAPS PharmSciTech; 2014 Dec; 15(6):1630-43. PubMed ID: 25145330
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Galactose-modified cationic liposomes as a liver-targeting delivery system for small interfering RNA.
    Sonoke S; Ueda T; Fujiwara K; Kuwabara K; Yano J
    Biol Pharm Bull; 2011; 34(8):1338-42. PubMed ID: 21804229
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nonviral pulmonary delivery of siRNA.
    Merkel OM; Kissel T
    Acc Chem Res; 2012 Jul; 45(7):961-70. PubMed ID: 21905687
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Self-crosslinked human serum albumin nanocarriers for systemic delivery of polymerized siRNA to tumors.
    Son S; Song S; Lee SJ; Min S; Kim SA; Yhee JY; Huh MS; Chan Kwon I; Jeong SY; Byun Y; Kim SH; Kim K
    Biomaterials; 2013 Dec; 34(37):9475-85. PubMed ID: 24050874
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The development of tertiary amine cationic lipids for safe and efficient siRNA delivery.
    Lin Z; Bao M; Yu Z; Xue L; Ju C; Zhang C
    Biomater Sci; 2019 Jul; 7(7):2777-2792. PubMed ID: 31041934
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.